Huabo Medicine-B (02142.HK): The application for new drug clinical trial of HBM7004 for the treatment of advanced solid tumors has been accepted by the National Medical Products Administration.

Wisdom Financial APP news, and Bo Pharmaceutical-B (02142.HK) announced that the China National Medical Products Administration (NMPA) has accepted the new drug clinical trial (IND) application for HBM7004 (a new B7H4xCD3 bispecific antibody for the treatment of advanced solid tumors). As disclosed in the announcement dated May 8, 2026, this is another progress made by the group after recently obtaining approval from the U.S. Food and Drug Administration for its IND application, to initiate the first phase I clinical trial of HBM7004 in the United States.